Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

24/07/2015 CVC: 20 Years Making Images Meaningful 17/07/2015 Presentation of the Industrial Ring 4.0 Project 13/07/2015 New International Success for B-Barcelona Consulting /BGC 02/07/2015 Creation of the Barcelona Institute of Science and Technology 26/06/2015 A Delegation From Porto Alegre Visits the Barcelona Synchrotron Park 17/06/2015 First light for PAU camera, designed to study dark energy
31 32 33 34 35 36 37 38 39 40 41